- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: Analysis of a US Payer Claims Database
Author(s):
Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.
Video Player is loading.
Video content above is prompted by the following question(s):
- How might conditions such as allergic rhinitis, anxiety, and asthma intersect with AD in terms of disease management and treatment response?
- Can you summarize the treatment patterns observed in this study before and after initiation of ruxolitinib cream, including the utilization of other topical and systemic therapies?
- Considering the baseline therapies used by patients prior to initiating ruxolitinib cream, does the distribution align with what you would expect in this patient population?
- Are there any specific patterns or trends in baseline therapy utilization that you find noteworthy or unexpected from this study?
Related Videos
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis
Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
Addressing Disparities in Inflammatory Skin Diseases in Darker Skin Tones
Related Content
